Introduction
Cancer patients of a given histologic type and stage may nonetheless have a different prognosis for length and quality of survival. The ability to delineate those factors which have signi®cant impacts on patients' disease and enable the clinician to better predict patient survival is clearly of great value. Information can be used to determine which patients will respond best to treatment, and those at greater risk for recurrence who may need closer follow up. Prostate cancer is the most common solid tumor in United States males and is the second leading cause of cancer death, clearly establishing a need for additional prognostic markers. 1 Additionally, as the treatment for carcinoma of the prostate evolves, it is important to have an accurate method to predict patient survival, disease recurrence and stage so that ef®cacy of a therapeutic modality in clinical trials can accurately be assessed.
Albumin, a readily available and inexpensive laboratory test that is frequently part of a standard preoperative evaluation, has been shown to be of value in predicting survival in such cancers as lung cancer, rectal cancer, colon cancer, cholangiocarcinoma, ovarian cancer, head and neck cancer, hepatocellular carcinoma, bladder carcinoma, renal cell carcinoma, melanoma, leukemia, and hormone refractory carcinoma of the prostate. 2 ± 13 In those studies where authors offered a reason for the relationship between albumin and survival, albumin as a marker of nutritional status was most commonly cited.
Albumin may also be low due to the presence of in¯ammatory mediators because of production by tumor and host cells in patients with malignancy. In¯ammatory mediators lower albumin in two ways. First, in¯amma-tory mediators increase the transcapillary escape rate of albumin such that albumin is lost to tissue spaces. 14 Second, in¯ammatory mediators such as IL-6, TNF, and acute phase reactants lead to lower production of albumin. 15 It is possible that albumin is an indirect measure of the level of in¯ammation, or the particular individual's response to the degree of in¯ammation that exists. In patients that are experiencing progressive disease, an increase in acute phase reactants such as C-reactive protein occurs such that there is a change in protein metabolism leading to the decreased production of albumin. Studies have shown that an increase in C-reactive protein indicates shortened survival time in patients with malignant disease. Additionally it has been shown that acute phase reactants have been used as an index of recurrence and as indicators of metastasis in neoplastic disease. 16 The level of albumin may identify those patients at greatest risk for recurrence, or conversely those patients that will respond best to treatment. While nutrition and in¯amma-tion are factors that are common to all patients with cancer, hypoalbuminemia has a further impact on those patients with carcinoma of the prostate. Ninety-®ve percent of testosterone is carried by sex hormone binding globulin, while the remaining 5% is carried by albumin. Carcinoma of the prostate is known to be hormonally sensitive to testosterone, but only the free, unbound testosterone has an impact on hormonally sensitive prostate cancer. It may be that those men with hormonally responsive carcinoma of the prostate and hypoalbuminemia may have a greater level of testosterone to act on prostate cancer cells that will contribute to recurrence. It should be noted that albumin-bound testosterone is thought to be biologically active, such that a low albumin may not have any effect upon biologically active testosterone levels. 18 However, clinical scenarios such as pregnancy alter apparent free testosterone concentration such that a low albumin results in an apparent free testosterone concentration that is greater than non-pregnant women. 19 It is known that 30 ± 40% of men who undergo a radical prostatectomy in clinically organ-con®ned localized carcinoma of the prostate will experience a disease recurrence. 20 Standard prognostic markers in widespread use include serum prostate speci®c antigen (PSA), tumor Gleason grade, and pathologic stage. In addition, our group and others have implicated ethnicity (ie Black vs Caucasian race), 21 prostatic acid phosphatase, 22 and a variety of cellular and molecular markers are under intense study as potential prognostic markers.
The goal of this retrospective review is to determine if pretreatment serum albumin is an independent prognostic marker of disease recurrence and pathological stage in a large cohort of radical prostatectomy patients.
Materials and methods
We retrospectively evaluated all patients with prostate cancer treated with radical prostatectomy at Walter Reed Army Medical Center between 15 April, 1990 and 3 December, 1996 in whom serum albumin was determined within 6 months of surgery. In order to determine serum albumin, Vitros ALB slides were used. The Vitros ALB slide is a dry multi-layered analytical element coated on a polyester support. When patient serum is deposited on the slide, the¯uid penetrates the reagent layer, bromocresol green (BCG) dye. The BCG dye binds albumin from the sample resulting in a shift in wavelength of the re¯ectance maxima of the free dye. The color complex that forms is measured by re¯ectance spectrophotometry where the amount of albumin bound dye is proportional to the concentration of albumin in the sample. Normal range as reported by Vitros was 3.5 ± 5.0 g/dl, with a sensitivity of 1.00 g/dl. Of note, our institution reported 3.5 and 3.8 as the value for an abnormally low albumin over the time period that this study covered.
The clinical information and follow-up were collected as part of the Department of Defense Center for Prostate Disease Research program. Walter Reed Army Medical Center has collected prospective and retrospective comprehensive clinical data on all patients with prostate cancer. As of 1 January, 1994, data collection was prospective on all new patients with prostate cancer. Similar retrospective data were also collected on all those treated since 1970 through inpatient and outpatient record reviews, and patient interviews. Standardized data collection forms for registration, staging, surgery, radiation treatment, hormonal treatment, cryotherapy and followup were developed and used. Data were collected by physicians and data managers, entered and maintained on a relational database by personal computer. The Center for Prostate Disease Research database has been approved by the Walter Reed Department of Clinical Investigation Institutional Review Board, and this retrospective study was also approved as an addendum.
Radical prostatectomy pathology reports were retrospectively reviewed and radical prostatectomy histological analysis was performed by standard processing at Walter Reed Army Medical Center in cases treated before May 1993. After May 1993, prostates were prospectively evaluated by whole-mount 2.25 mm step sectioning at the Armed Forces Institute of Pathology. Organ-con®ned prostate cancer (T1, T2) was de®ned as no capsular penetration, positive margins, seminal vesicles or lymph nodes. Extraprostatic disease (T3, T4) was de®ned as any cancer on any inked margin or any capsular penetration.
Histopathological grading was done according to the Gleason system 23 and the World Health Organization (WHO) method of glandular differentiation. 24 The value grade used in this study is a combination of the WHO and Gleason systems. Gleason grades 2 ± 4 or WHO grade well is considered grade well, Gleason grades 5 ± 7 or WHO grade moderate is considered grade moderate and Gleason grades 8 ± 10 or WHO grade poor is considered grade poor. Staging was based on the modi®ed Whitmore ± Jewett system and the 1992 TNM classi®cation. 25 Serological recurrence of prostate cancer based on the Abbott IMx PSA assay was de®ned as two successive measurements greater than 0.2 ng/ml. 26 
Statistical analysis
Logistic regression analysis was used to study the relationship of ®ve variables (albumin, age, race, PSA and grade) to pathological stage to assess the clinical usefulness of albumin as a predictor of nonorgan-con®ned disease. Pathological stage was a dichotomous categorical variable (T1 or T2, and T3 or T4), as was albumin (less than or equal to 3.7, or greater than or equal to 3.8), and race (African American or not African American). Grade was a categorical variable with three levels (well, moderate, or poor). The choice to use 3.7 was derived by averaging the two values (3.5 and 3.8) that were reported as abnormally low over the time period that the patients were evaluated. Age and log-transformed PSA entered the model as continuous variables. Cox regression was used to study the relationship of these same ®ve independent variables to PSA recurrence. Table 1 provides the distribution by age, race, disease stage, grade, pretreatment albumin, PSA values, and pathological stage for the study cohort of 354 radical prostatectomy patients. Albumin was analyzed for clinical usefulness in predicting pathologic stage and initial disease recurrence by PSA elevation following radical prostatectomy. Albumin ranged from 3.0 to 5.4 with a mean of 4.1 and a median of 4.0 g/dl. There was essentially no difference between the albumin mean of 4.1 for the 145 patients with organcon®ned disease and the mean of 4.0 for the 209 patients with nonorgan-con®ned disease. However, patients with the lowest albumin values consistently had the most extraprostatic disease as seen in Figure 1 , a histogram illustrating the relationship of albumin to pathological stage. When albumin was 3.7 the percentage of patients with stage T3 or T4 disease was 74.4%. When albumin was 3.8 the percentage of patients with T3 or T4 disease was 56.9%. This represents a statistically signi®cant difference (P 0.032 based upon Fisher's exact test). Albumin was treated as a dichotomous variable ( 3.7, 3.8) in all subsequent analysis. Table 2 shows the univariate relationship of albumin, age, race, pretreatment PSA, and grade to pathological stage. The simultaneous in¯uence of these ®ve variables on pathological stage was examined using logistic regression with backward elimination of insigni®cant variables Age and race were statistically insigni®cant, while PSA (P`0.001), grade (P`0.001), as well as albumin (P 0.047) were signi®cant independent predictors of extraprostatic disease.
Results
There were 91 recurrences of disease among the 354 patients. Figure 2 illustrates the results of Kaplan ± Meier recurrence-free survival analysis by albumin level ( 3.7 and 3.8). These survival curves were not signi®cantly different (log rank P 0.59). In a multivariable Cox regression analysis with albumin, age, race, pretreatment PSA and grade in the model, albumin remained a nonsigni®cant predictor of disease recurrence (P 0.916).
Discussion
To our knowledge, this is the ®rst study to analyze pretreatment albumin levels as a marker for pathological stage and disease recurrence for prostate cancer, speci®-cally that population undergoing radical prostatectomy as their primary, initial treatment modality. While albumin has been shown to be a statistically signi®cant marker for survival in many other primary cancers, including lung cancer, rectal cancer, colon cancer, cholangiocarcinoma, ovarian cancer, head and neck cancer, hepatocellular carcinoma, bladder carcinoma, renal cell carcinoma, melanoma, leukemia and hormone refractory carcinoma of the prostate, 2 ± 13 our results indicate that albumin has no value as a marker for predicting disease recurrence as measured by elevation in PSA after surgery for clinically localized prostate cancer. Figure 1 Serum pretreatment albumin values by pathological stage T3 or T4 in 354 radical prostatectomy patients. At a cut-off point of 3.7 there is a signi®cant relationship of albumin to pathologic stage; when 3.7, 74.4% of patients had T3/T4 disease whereas when 3.8 only 56.9% had extraprostatic disease (P 0.032). This relationship remained signi®cant in multivariable analysis (see text).
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One reason why albumin may not be predictive of disease recurrence in prostate cancer where it was shown to be predictive of survival in many other primary cancers is that the men selected for radical prostatectomy as their treatment modality for prostate cancer are generally healthy without signi®cant co-morbid disease that would preclude them from undergoing an extensive surgical procedure, and additionally are thought to have organ-con®ned disease. This is in contrast to other cancers and prostate patients with more advanced disease who might be offered radiation or hormone ablation as their Figure 2 Kaplan ± Meier recurrence-free survival curves for 354 radical prostatectomy patients by serum pretreatment albumin level. The mean follow-up for the 354 patients was 50.0 months. Ninety-one patients (25.7%) had a PSA recurrence during follow-up, six men died during follow-up with no PSA recurrence, and 257 patients were alive at last follow-up with no PSA recurrence (17 of 257 were lost to follow-up within 1 y of surgery, the rest had at least 1 y of follow-up). Albumin in prostate cancer prognosis E Richter et al treatment modality. Additionally, due to effective screening with PSA, disease is detected at an earlier stage, and deleterious effects of the disease as a result of metastasis and resulting cachexia seen in other primary cancers with less effective screening methods that might alter albumin levels, are not as frequent in prostate cancer. This scenario is not unlike breast cancer, a disease in which there is an effective screening method, and to our knowledge has not been shown to have albumin as a predictive marker. To our surprise, albumin was predictive of pathological stage when a cutoff of 3.7 or less was used. Patients with low pretreatment albumin were signi®cantly more likely to have nonorgan-con®ned carcinoma of the prostate (T3 or T4 disease). However, it should be noted that patients with an albumin level less than 3.7 represented only 12.1% of the study group. Factors that may account for this are the increase in in¯ammatory cytokines that would be expected to be present in patients with nonorgancon®ned disease. Additionally, as mentioned earlier, a theoretical possibility exists that a low albumin level may increase the amount of free testosterone, in¯uencing the progression of hormone sensitive tumors and thus predisposing a patient to more advanced disease at presentation. However, it must be noted that this is a relatively small, single-institution study and these provocative ®ndings must be con®rmed in larger studies.
While there does not appear to be a role for albumin in predicting disease recurrence, these results indicate that albumin may have a role in the assessment of newly diagnosed patients for determining stage. In particular, as multiple prognostic factors are tested in traditional statistical models and in neural network studies, albumin should be examined further as a putative staging factor. Furthermore, albumin should be examined as a risk factor for clinical prostate cancer diagnosis.
Conclusion
Albumin is not an effective marker for predicting serologic disease recurrence in men undergoing radical prostatectomy. However, albumin, which is widely available and inexpensive, may be a marker for determining the relative risk of nonorgan-con®ned carcinoma of the prostate. Further study of this serum marker is indicated.
